Provexis Share Discussion Threads

[banshee] 27/11/2016 20:57

" FF does the same job only better." of course you have the evidence in the form of large scale clinical studies to back up this claim don't you? How many strokes has Fruitflow been shown to prevent?

[nestoframpers] 27/11/2016 20:52

Libra if your at risk of a stroke your Dr will put you on Aspirin , FF does the same job only better.

[librag] 27/11/2016 19:37

NOR; the majority of Brits don't buy FF because of many reasons, but as it doesn't help prevent strokes, that isn't one of them.
re. the blue channel; as you say, our running costs are around £200K per annum, which is why, unless we improve profitability rapidly, a fundraising is on the cards, probably next year. The BP trial might need a significant fund-raise, personally I hope so.

[traidemark] 27/11/2016 13:32

What is the possibility of PXS being taken out,

Sorry fairly new here so excuse the ignorance, but my experience of this sector leads me to ascertain that a big boy will come along and take out a company once the work is done

Any ideas of how PXS could resist this or at what price any potential offer would be, could the recent rise indicate an offer is being tabled

thanks

[sleveen] 27/11/2016 11:06

A randomised controlled trial comparing a dietary antiplatelet, the water-soluble tomato extract Fruitflow, with 75 mg aspirin in healthy subjects.
O'Kennedy N1, Crosbie L1, Song HJ1, Zhang X1, Horgan G2, Duttaroy AK3.
Author information
Abstract
BACKGROUND/OBJECTIVES:

Increasing numbers of food ingredients are gaining acknowledgement, via regulated health claims, of benefits to human health. One such is a water-soluble tomato extract, Fruitflow (FF), a dietary antiplatelet. We examined relative platelet responses to FF and to 75 mg aspirin (ASA) in healthy subjects.
SUBJECTS/METHODS:

A total of 47 healthy subjects completed a double-blinded randomised controlled trial following a crossover design. Acute and 7-day treatments with 75 mg ASA were compared with control with and without concomitant FF, over a 5-h timecourse. Platelet aggregation response agonist, platelet thromboxane A2 release, plasma clotting times and time to form a primary haemostatic clot (PFA-100 closure time, TTC) were measured.
RESULTS:

Administration of all treatments lowered platelet function and thromboxane A2 generation, and extended the TTC, relative to baseline (P<0.001) and to control (P<0.001). Plasma clotting times were not affected. A single 75 mg dose of ASA showed approximately equal efficacy to a dose of FF, whereas daily 75 mg ASA was approximately three times as effective after 7 days (P=0.002). Platelet responses were heterogenous with distinct weak and strong responder groups. Weak ASA responders retained a functional platelet response to collagen agonist and were responsive to FF. Concomitant FF and ASA did not lead to significant additive effects.
CONCLUSIONS:

The suppression of platelet function observed after consuming FF is approximately one-third that of daily 75 mg ASA. The reversible action of FF renders it less likely to overextend the time to form a primary haemostatic clot than ASA, an important safety consideration for primary prevention.European Journal of Clinical Nutrition advance online publication, 23 November 2016; doi:10.1038/ejcn.2016.222

[sleveen] 27/11/2016 11:05

A randomised controlled trial comparing a dietary antiplatelet, the water-soluble tomato extract Fruitflow, with 75 mg aspirin in healthy subjects.
O'Kennedy N1, Crosbie L1, Song HJ1, Zhang X1, Horgan G2, Duttaroy AK3.
Author information
Abstract
BACKGROUND/OBJECTIVES:

Increasing numbers of food ingredients are gaining acknowledgement, via regulated health claims, of benefits to human health. One such is a water-soluble tomato extract, Fruitflow (FF), a dietary antiplatelet. We examined relative platelet responses to FF and to 75 mg aspirin (ASA) in healthy subjects.
SUBJECTS/METHODS:

A total of 47 healthy subjects completed a double-blinded randomised controlled trial following a crossover design. Acute and 7-day treatments with 75 mg ASA were compared with control with and without concomitant FF, over a 5-h timecourse. Platelet aggregation response agonist, platelet thromboxane A2 release, plasma clotting times and time to form a primary haemostatic clot (PFA-100 closure time, TTC) were measured.
RESULTS:

Administration of all treatments lowered platelet function and thromboxane A2 generation, and extended the TTC, relative to baseline (P<0.001) and to control (P<0.001). Plasma clotting times were not affected. A single 75 mg dose of ASA showed approximately equal efficacy to a dose of FF, whereas daily 75 mg ASA was approximately three times as effective after 7 days (P=0.002). Platelet responses were heterogenous with distinct weak and strong responder groups. Weak ASA responders retained a functional platelet response to collagen agonist and were responsive to FF. Concomitant FF and ASA did not lead to significant additive effects.
CONCLUSIONS:

The suppression of platelet function observed after consuming FF is approximately one-third that of daily 75 mg ASA. The reversible action of FF renders it less likely to overextend the time to form a primary haemostatic clot than ASA, an important safety consideration for primary prevention.European Journal of Clinical Nutrition advance online publication, 23 November 2016; doi:10.1038/ejcn.2016.222

[nestoframpers] 27/11/2016 10:42

Well this went to 17p on 'gold rush' sentiment , who knows where this riswe will end . If the Chinese know they have big plans for FF then they will be buying shares , more than happy to take them off PO LTHs at this price if that is the case.

[bareknee] 27/11/2016 09:46

I suspect it's something to do wuth their business model. Mayve the higher revenue figures are what their sellers are taking from the public, whereas the lower one is the IFRS figure reported by the company ?

To be honest I think they're too far apart for that to be the only explanation, but it's the best I can come up with.

[gix er] 27/11/2016 09:02

lol,

so is Aim global by the looks of it :-)

Nah! i think your revenue might be nearer the mark.

Saying that. Its not easy getting accurate figures on these type of companies.

[bareknee] 27/11/2016 08:52

Gixer

Haha

I was ranting from memory so fair play on the number of products !

Back in 2014 their "About Us" page on their website stated their 2013 turnover was 2 Billion Pesos, which is roughly £30 million, so my memory isn't totally goosed

Unless they've changed the way they declare turnover then they must have made a massive step up in 2014 which is quite remarkable and suggests an average sale per product of 10 million USD. That'd beg the question as to where's our share of the FF product is ?

I'll cheekily add ...

So By-Health is less than twice the size of Alliance in Global :)

To be fair By-Health is growing quickly. It's good news mate, but it's unlikely to be the second coming that some are making it out to be.

BB

[gix er] 27/11/2016 07:41

BB,

"The by-health RNS reminds me of the talk on the boards when the Phillipine pyramid seller launched a FF product. Some were then saying that if every seller of theirs sold just packets we'd all be rich, but people got arsy when I pointed out that the company had hundreds of products and only turned over ~ 50 million GBP/ year"

People got "arsy" with you??? Nah! I don't believe it.

But if they did it might have been something to do with the slightly exaggerated amount of products quoted?? (i make it between 20 -30)


Or if this link is correct then maybe your turnover was a bit off as well?
hxxps://www.businessforhome.org/2016/06/alliance-in-motion-global-classified-as-triple-a-opportunity/

The company has achieved in 2014 $180 Million growing in 2015 to S200 Million in revenue.

JSL.

Products and revenue aside, I still believe Aim Global was a good move by DSM as between the company (Aim Global)and its sales people they have been getting the "fruitflow" word out there. More so than any other product. IMO of course.

[wheelds] 26/11/2016 23:34

As of 26/11/16 Bar chart still positive:

hxxps://www.barchart.com/stocks/quotes/PXS.LS/opinion
that http

My guess is the China company is now buying into our Provexis to become a major share holder just like
DSM did in the good old days when the share price rose to 15p/22p from 0.6p over around a year before falling back as Coca Cola collaboration fell through after a year and DSM holdings dropped too.

We have a great health product which is now recognised across Europe,(EFSA) America, (GRAS) and soon across China.

[bareknee] 26/11/2016 23:25

Wheelie

From your own post, turnover 361 Million USD, or about 300 Million GBP

That's like 3 Healthspans.

Keep up the good work though. With luck the share price will get driven higher and I'll take some more off the table.

I bet you've sold a few in the last week or so too havn't you ? Nothing wrong with that btw, fair play to you for getting your timing right.

[bareknee] 26/11/2016 23:21

Lafin

Looking at that article it looks the Chinese middle class earn between 12,000 and 500,000 USD. I own shares in Chimed who, among other things, sell health products to that demographic,

There's definitely a large Chinese marke t to aim at, probably in the order of 50 to 100 million, buthe overall number of "middle class" Chinese hides a demographric shift in that the percentage of them under 30 is increasing, and they're less likely to be worried about CVD.

The by-health RNS reminds me of the talk on the boards when the Phillipine pyramid seller launched a FF product. Some were then saying that if every seller of theirs sold just packets we'd all be rich, but people got arsy when I pointed out that the company had hundreds of products and only turned over ~ 50 million GBP/ year

The by-health link will probably be fairly significant, but it's not as massive as some posters believe. Some, like Guns, have a genuine belief in it, others are just ramping, so there's no surprises there then !

BB

[wheelds] 26/11/2016 22:54

The China company we are now in Collaboration with:-


that's http

By-Health
Market Cap As of August 2016
$3.1 Billion
Industry Household & Personal Products
Founded 1995
Country CHINA / HONG KONG
Employees 2,581
Sales $361 M

[librag] 26/11/2016 20:43

Doubt it. All lafin means is to contradict in a pseudo-intelligent fashion. I've advised her to keep taking the medication but ...

[nestoframpers] 26/11/2016 18:04

I think lafin means that no one knows the future ? imo knowing when to sell ie to not feed the greed is sophisticated .

[gunsofmarscapone] 26/11/2016 16:03

The opposite of an unsophisticated one, look at GKP etc etc.

[lafin] 26/11/2016 14:14

Look at diagram of earnings of Chinese people on



According to this a rich group of 1.4 million are really only ones who may be able to afford Fruitflow

Rest earn less than $12,000 per annum -majority MUCH less.

[lafin] 26/11/2016 14:10

No such thing as a sophisticated investor.

[gunsofmarscapone] 26/11/2016 11:58

Well Bareknee, that remains to be seen however, there is plenty of evidence that many who entered into this equity far too early are also exiting early, in some cases exiting and then panic buying back at a higher share price

Compounding impatience with yet more impatience THE most negative attribute for any investor, particularly value investors.

I'm more than 100% up and will in no way sell a single share. Eventually and hopefully, the risks will shed and then I will be happy to release a few to what will most probably be sophisticated investors and institutions.